TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04188145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine
Description: Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine
Description: Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).
Study: NCT02287922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Study: NCT03182426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Systemic CD34+ stem cell mobilization for beta-cell repair
Study: NCT04188145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab
Study: NCT00446173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 IV Daily Over 3 Hours x 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV Daily Over 4 Hours x 2 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg Subcutaneously Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/kg Subcutaneously Once Daily
Study: NCT03669289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model of primary care
Description: The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
Study: NCT00639626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir [rDNA origin] injection
Description: Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
Study: NCT03268291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard outpatient observation
Description: Outpatient management according to Ministry of health standards

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communicational program Trust
Description: The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services.
Study: NCT00367835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (Guanfacine hydrochloride)
Description: Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03850535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
Study: NCT03182426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Systemic CD34+ stem cell mobilization for beta-cell repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: T-cell depletion
Study: NCT03850535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
Study: NCT03182426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: T-cell depletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anti-inflammatory
Study: NCT02079688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB011, 2 % (Water/Oil/Water) emulsion of hgd40
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple W/O/W formulation, active ingredient-free vehicle
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Study: NCT03182426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Beta-cell regeneration
Study: NCT02659436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal-linguistic CBT
Description: Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery-based CBT
Description: Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
Study: NCT03182426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Beta-cell regeneration
Study: NCT04481360

Intervention type: DEVICE
Intervention: CT of the chest
Description: Degree of affection on the lung infected by COVID19
Study: NCT01590160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: IV, Using dose from Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: IV, Using dose from Phase I
Study: NCT02508428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Replacement with crosslinked Marathon polyethylene
Description: Comparison of Marathon and Enduron polyethylene

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Replacement with noncrosslinked Enduron polyethylene
Study: NCT02078128

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral beta-glucans
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Study: NCT01740596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse® System Counterpulsation
Description: The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
Study: NCT03051048

Intervention type: PROCEDURE
Intervention: Reperfusion

Intervention type: PROCEDURE
Intervention: Reperfusion
Study: NCT01675882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 50 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
Study: NCT02078128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sugar powder
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Study: NCT02430116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Description: In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic postconditioning
Description: In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
Study: NCT00216216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV q 3 weeks
Study: NCT02679170

Intervention type: DRUG
Intervention: Crizotinib
Description: Treatment with crizotinib following routine clinical practice
Study: NCT00805324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: desloratadine syrup; 5.0 mL once daily for 28 days
Study: NCT01675882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
Study: NCT02226211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q intubation laryngeal airway
Description: The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu-Aura i laryngeal mask
Description: The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (\> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT.
Study: NCT02779244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Weight bearing + Cam Boot
Description: Patients will be transitioned to weight bearing as tolerated in a cam boot.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Weight Bearing + Cam Boot
Description: Subject will be transitioned to non weight bearing cam boot, standard treatment.
Study: NCT02785068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: Oligoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: Nanoliposomal irinotecan
Study: NCT04364178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus Specific T- Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus Specific T-Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
Study: NCT03810716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Platform
Description: The participants will see the interactive platform.
Study: NCT02785068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: folinic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Chemotherapy
Study: NCT03360799

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01875978

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytosterols & placebo
Description: Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
Study: NCT02486874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoreSkin
Description: a human acellular dermal matrix
Study: NCT05436730

Intervention type: DEVICE
Intervention: Ambulatory blood pressure measurement device
Description: Assessment of the 24-h blood pressure profile
Study: NCT02291952

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal schedule
Study: NCT00801398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR
Description: Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
Study: NCT03521245

Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
Study: NCT02291952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal schedule
Study: NCT03521245

Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.

Intervention type: OTHER
Intervention: Transcriptome analysis
Description: Analysis of RNA-seq data using the Oncobox algorithm.

Intervention type: OTHER
Intervention: Transcriptome analysis
Description: Analysis of RNA-seq data using the Oncobox algorithm.
Study: NCT03741764

Intervention type: DEVICE
Group type: OTHER
Intervention: Vivosorb
Description: Resorbable implant device
Study: NCT02561975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double pulmonary diffusing
Description: Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc
Study: NCT00420524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906
Study: NCT03423992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cells
Description: chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
Study: NCT01305551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, Oral, 5 mg, once on Day 1 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, Oral, 5 mg, once on Day 1 only
Study: NCT03521245

Intervention type: DRUG
Intervention: Trastuzumab
Description: Standard Trastuzumab treatment regimen recommended for breast cancer

Intervention type: DRUG
Intervention: Trastuzumab
Description: Standard Trastuzumab treatment regimen recommended for breast cancer

Intervention type: DRUG
Intervention: Chemotherapy
Description: Standard chemotherapy regimen recommended for breast cancer
Study: NCT01022099

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantation of a Total Knee Arthroplasty
Description: In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides.
Study: NCT01305551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 500 mg, once on Day 1 only
Study: NCT03724552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (Participants ages 9-17)
Description: Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
Study: NCT01022099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a Total Knee Arthroplasty
Description: In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides.
Study: NCT04305847

Intervention type: OTHER
Intervention: perioperative satisfaction assessment
Description: Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
Study: NCT04009395

Intervention type: OTHER
Intervention: Pregnant Women qualitative interviewing
Description: one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.

Intervention type: OTHER
Intervention: Midwives qualitative interviewing
Description: one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.